Please assess the completion status of the following clinical trial:

Trial Title: Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically or cytologically documented, unresectable, locally advanced or metastatic solid tumor~* Must have available archived tumor tissue (formalin-fixed paraffin-embedded) \[FFPE\].~* 18 years of age or older.~* Have measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST, v1.1) or increased CA-125 (ovarian cancer) or PSA (prostate cancer) and/or CA 19-9 (pancreatic cancer).~* Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1.~* Have adequate organ function~* Able to take oral medications.~* Willing and able to provide informed consent.~* Sexually active patients must be willing to use an acceptable method of contraception.~* Females of childbearing potential must have a negative serum pregnancy test at screening.~* Willing and able to comply with all study procedures.~Part 2 Dose Expansion Tumor Types:~* Breast and ovarian cancer patients with deleterious or pathogenic BRCA mutations who have received no more than 4 prior regimens for metastatic disease.~* Prostate or pancreatic cancer patients with deleterious or pathogenic BRCA mutations who have received no more than 2 prior regimens for metastatic disease.~* Small cell lung cancer (SCLC) patients who have received no more than one prior regimen for SCLC.~* Ewing's sarcoma patients who have received no more than 3 prior regimens for metastatic disease.~Exclusion Criteria:~* Part 2 Expansion: Prior treatment with a PARP inhibitor.~* Has history of central nervous system (CNS) metastasis.~  \* Exception: In patients with SCLC, history of adequately treated brain metastasis who do not require corticosteroids for management of CNS symptoms.~* Has had major surgery within 28 days before Cycle 1, Day 1.~* Has active peptic ulcer disease.~* Active gastrointestinal tract disease with malabsorption syndrome.~* Pregnant or breastfeeding at screening or planning to become pregnant (in each case, either oneself or one's partner) at any time during the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Talazoparib (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).